Trial Profile
A Long Term Extension study of E2080 in Lennox-Gastaut Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs Rufinamide (Primary)
- Indications Lennox-Gastaut syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Co Ltd
- 27 Apr 2018 Results from NCT01151540, NCT01405053, NCT01146951 and 2 other studies, presented at the 70th Annual Meeting of the American Academy of Neurology
- 23 May 2016 New trial record